505 results on '"Rossi, Jean-François"'
Search Results
2. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
3. Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
4. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
5. Environmental Risk Factors for Non-Hodgkin's Lymphoma: A Population-Based Case-Control Study in Languedoc-Roussillon, France
6. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
7. Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer.
8. Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study
9. Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers
10. Real-world data on bio-clinical follow-up after vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in 216 patients with hematological malignancies
11. FROM ALLOGENIC TRANSPLANTATION TO PRECISION IMMUNE THERAPY
12. REAL-LIFE STUDY OF BIO-CLINICAL FOLLOW-UP AFTER BNT162b2 mRNA COVID-19 (BNTCV) VACCINATION IN 235 PATIENTS (PTS) INCLUDING 225 WITH HEMATOLOGICAL MALIGNANCIES (HM).
13. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
14. All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity
15. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling
16. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6
17. The NF-κB member p65 controls glutamine metabolism through miR-23a
18. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program
19. Phase I Study of Atacicept in Relapsed/Refractory Multiple Myeloma (MM) and Waldenström's Macroglobulinemia
20. Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19
21. INFLAMMATION AND CANCER
22. Induction of angiogenesis by normal and malignant plasma cells
23. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
24. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
25. Tocilizumab in Treatment for Patients With COVID-19
26. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
27. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
28. Controlled Epstein–Barr virus reactivation after allogeneic transplantation is associated with improved survival
29. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
30. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma
31. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro
32. Evaluation of antitumor effects of two vine stalk oligomers of resveratrol on a panel of lymphoid and myeloid cell lines: Comparison with resveratrol
33. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells
34. The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
35. Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer
36. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays
37. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells
38. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
39. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis
40. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
41. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
42. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95
43. Evaluation of Endometrial Inflammation by Quantification of Macrophages, T Lymphocytes, and Interleukin-1 and -6 in Human Endometrium
44. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
45. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
46. Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells
47. Cytokine Pathways in Myeloma Growth and Survival
48. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma
49. Targeting NF-κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth
50. Microarray-based understanding of normal and malignant plasma cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.